InventisBio Co Ltd Class A 688382
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 9.39
- Day Range
- CNY 9.16–9.49
- 52-Week Range
- CNY 7.40–21.57
- Bid/Ask
- CNY 9.40 / CNY 9.42
- Market Cap
- CNY 5.42 Bil
- Volume/Avg
- 5.7 Mil / 7.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.12
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 222
- Website
- http://www.inventisbio.com
Comparables
Valuation
|
Metric
|
688382
|
02315
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.80 | 4.39 | 2.73 |
Price/Sales | 28.12 | 4.79 | 39.42 |
Price/Cash Flow | — | — | — |
Price/Earnings
688382
02315
NYKD
Financial Strength
|
Metric
|
688382
|
02315
|
NYKD
|
|---|---|---|---|
Quick Ratio | 14.92 | 1.02 | 8.43 |
Current Ratio | 14.99 | 1.30 | 8.43 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
688382
02315
NYKD
Profitability
|
Metric
|
688382
|
02315
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −11.85% | −13.53% | −18.26% |
Return on Equity (Normalized) | −12.67% | −37.28% | −23.64% |
Return on Invested Capital (Normalized) | −14.09% | −20.22% | −26.98% |
Return on Assets
688382
02315
NYKD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mvzkvcyxwf | Xvyd | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wqwvwbx | Fyncdd | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ypwymskvc | Xbgvpq | $106.7 Bil | |
MRNA
| Moderna Inc | Wwpflly | Zzsf | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Xtgvcpj | Yqnd | $22.4 Bil | |
ARGX
| argenx SE ADR | Kkgjfrc | Ybp | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zpyvvmdqc | Bswhfk | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dcpjjdmd | Mfybhd | $14.6 Bil | |
INCY
| Incyte Corp | Xpjmhpmz | Gtcbkrp | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nfpbdknxw | Cdqvy | $12.6 Bil |